Search results
J&J to Lead in Atopic Dermatitis Treatment with Recent Acquisition
New Jersey Business Magazine· 6 days agoJohnson & Johnson has entered into a definitive agreement to acquire Proteologix, Inc. for $850...
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
Morningstar· 6 days agoProteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic
Johnson & Johnson to acquire Proteologix for $850 million
Reuters via Yahoo Finance· 6 days agoProteologix's antibody PX128 is ready to enter early-stage development for moderate to severe atopic...
Johnson & Johnson plans $850M Proteologix acquisition
NJBIZ· 1 day agoA May 16 press release announced the all-cash deal. The New Brunswick-based pharma giant said the move will add depth to its dermatology portfolio by boosting its position to address
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Zacks via Yahoo Finance· 5 days agoThis week, Bayer BAYRY released its first-quarter results. J&J JNJ announced that it will acquire a...
Chart Review Highlights Unique AD Features in Older Patients
Medscape· 2 days agoMore research is "needed to elucidate the unique features of elderly AD in pathophysiology and...
Johnson & Johnson Strikes $850 Million Deal to Boost Dermatology Portfolio
Morningstar· 6 days agoJohnson & Johnson has agreed to buy privately-held biotechnology company Proteologix for an initial $850 million in cash in a deal that bolsters the healthcare giant's dermatology portfolio.
Earnings call: Arcutis Biotherapeutics reports strong Q1 2024 growth By Investing.com
Investing.com· 7 days agoArcutis Biotherapeutics (NASDAQ:ARQT) has announced robust financial results for the first quarter...
Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Benzinga via AOL· 5 days agoProteologix’s portfolio includes: PX128, a bispecific antibody targeting IL-13 plus TSLP, which is...
Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
GuruFocus.com via Yahoo Finance· 7 days agoArcutis Biotherapeutics Inc (NASDAQ:ARQT) is poised for potential market expansion with the upcoming FDA PDUFA target date for its sNDA for atopic dermatitis</ ...